Alloy Therapeutics Enters into a Multi-Year Strategic Collaboration with Pfizer to Develop New Antibody Discovery Platform
Shots:
- Alloy Therapeutics has entered into a strategic collaboration with Pfizer to develop a platform designed to improve Pfizer’s capability to discover potent, specific, and effective antibodies for targets that are challenging to address with current antibody discovery technologies, including the use of Alloy’s ATX-Gx platform
- As per the agreement, Alloy will receive an upfront payment and eligible for pre-specified preclinical to commercial milestone payments on products developed using the platform
- Alloy has expanded its murine platforms by adding new strains, including ATX-GL with a full human lambda repertoire and ATX-GKH (hyperimmune strain) for enhanced antigen-specific B-cell generation and IgG class switching
Ref: Alloy Therapeutics | Image: Alloy Therapeutics & Pfizer
Related News:- Alloy Therapeutics Partners with Sanofi to Advance Innovative Therapeutics in the CNS Space
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
